IP Library Granted Patent US 12,508,062
Granted Patent B2
US 12,508,062 · App. 18/172,133 · Granted Dec 30, 2025

Cryogenic therapy systems and methods

Inventors: John Spranger (Hingham, MA); Roy Winston (Tampa, FL); Jared Ham (Severn, MA); Jonathan Slonin (Palm City, FL)
Assignee: Pacira CryoTech, Inc.
A61B18/0218A61B2018/00434A61B2018/025A61B2018/0293
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,062
App. No.
18/172,133
Granted
Dec 30, 2025
Kind
B2
Abstract

A method of interrupting sympathetic stimulation to the cardiovascular system of a patient in need thereof includes navigating a probe of a hand-held cryogenic therapy apparatus to a stellate ganglion or an autonomic tissue area peripheral to the stellate ganglion of the patient, the probe including a needle configured to produce a cooling zone for focused cryogenic therapy, aligning the needle with one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion, and producing the cooling zone to provide cryogenic therapy to the desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion at a temperature sufficient to cause axonotmesis of the nerves.

Claims (38)

1 . A method of interrupting sympathetic stimulation to the cardiovascular system of a patient in need thereof, comprising:

navigating a probe of a hand-held cryogenic therapy apparatus to a stellate ganglion or an autonomic tissue area peripheral to the stellate ganglion of the patient, the probe comprising a needle configured to produce a cooling zone for focused cryogenic therapy;

aligning the needle with one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion; and

producing the cooling zone to provide cryogenic therapy to the desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion at a temperature sufficient to cause axonotmesis of the nerves.

2 . The method of claim 1 , wherein the temperature is between −80° C. and −90° C.

3 . The method of claim 2 , wherein the cryogenic therapy to the one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion is administered for between 1 minute and 4 minutes.

4 . The method of claim 1 , wherein navigating the probe to the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion comprises inserting the probe percutaneously or inserting the probe in an open surgery.

5 . The method of claim 1 , wherein navigating the probe to the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion comprises guiding the probe using fluoroscopic or ultrasound imaging.

6 . The method of claim 1 , further comprising inserting one or more dilators or guides into the patient to form a pathway for navigation of the probe to the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion.

7 . The method of claim 1 , wherein producing the cooling zone comprises forming an ice-ball about an outer surface of the needle.

8 . The method of claim 1 , wherein the patient has suffered from or is at risk of suffering from atrial tachyarrhythmia, refractory atrial tachyarrhythmia, ventricular arrhythmia, ventricular tachycardia, ventricular fibrillation, refractory ventricular arrhythmia, refractory ventricular tachycardia, or refractory ventricular fibrillation.

9 . The method of claim 1 , wherein the patient has suffered from or is at risk of suffering from a cardiac arrhythmia selected from the group consisting of long QT syndrome, ischemic cardiomyopathy, dilated cardiomyopathy, valvular heart disease, acute myocardial infarction, and ongoing myocardial ischemia, and combinations thereof.

10 . The method of claim 1 , wherein the patient has an implantable cardioverter-defibrillator (ICD).

11 . The method of claim 1 , wherein the cryogenic therapy results in temporarily interruption of sympathetic stimulation to the cardiovascular system for up to 1, 2, 3, 4, 5, or 6 months.

12 . The method of claim 1 , wherein the cryogenic therapy causes regeneration of the treated nerves of stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion.

13 . The method of claim 1 , wherein the cryogenic therapy causes regeneration of one or more sodium channels of the treated nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion.

14 . The method of claim 1 , wherein the one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion comprise one or more desired nerves of a paravertebral chain.

15 . The method of claim 14 , wherein the one or more desired nerves of the paravertebral chain comprises one or more desired nerves of one or more of a C7 region of the paravertebral chain, a C8 region of the paravertebral chain, a T1 region of the paravertebral chain, and a T2 region of the paravertebral chain.

16 . A method of treating a patient suffering from cardiac electrical storm, comprising:

providing cryogenic therapy to one or more desired nerves of a stellate ganglion or an autonomic tissue area peripheral to the stellate ganglion of the patient, wherein providing the cryogenic therapy comprises:

navigating a probe of a hand-held cryogenic therapy apparatus to the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion of the patient, the probe comprising a needle configured to produce a cooling zone for focused cryogenic therapy;

aligning the needle with the one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion; and

producing the cooling zone to provide cryogenic therapy to the desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion at a temperature sufficient to cause axonotmesis of the nerves.

17 . The method of claim 16 , further comprising selecting or identifying a patient who has suffered from or is at risk of suffering from cardiac electrical storm.

18 . The method of claim 16 , wherein the temperature is between −80° C. and −90° C.

19 . The method of claim 18 , wherein the cryogenic therapy to the one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion is administered for between 1 minute and 4 minutes.

20 . The method of claim 16 , wherein navigating the probe to the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion comprises inserting the probe percutaneously or inserting the probe in an open surgery.

21 . The method of claim 16 , wherein navigating the probe to the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion comprises guiding the probe using fluoroscopic or ultrasound imaging.

22 . The method of claim 16 , further comprising inserting one or more dilators or guides into the patient to form a pathway for navigation of the probe to the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion.

23 . The method of claim 16 , wherein producing the cooling zone comprises forming an ice-ball about an outer surface of the needle.

24 . The method of claim 16 , wherein the patient has suffered from or is at risk of suffering from atrial tachyarrhythmia, refractory atrial tachyarrhythmia, ventricular arrhythmia, ventricular tachycardia, ventricular fibrillation, refractory ventricular arrhythmia, refractory ventricular tachycardia, or refractory ventricular fibrillation.

25 . The method of claim 16 , wherein the patient has suffered from or is at risk of suffering from a cardiac arrhythmia selected from the group consisting of long QT syndrome, ischemic cardiomyopathy, dilated cardiomyopathy, valvular heart disease, acute myocardial infarction, and ongoing myocardial ischemia, and combinations thereof.

26 . The method of claim 16 , wherein the patient has an implantable cardioverter-defibrillator (ICD).

27 . The method of claim 16 , wherein the cryogenic therapy results in temporarily interruption of sympathetic stimulation to the cardiovascular system of the patient for up to 1, 2, 3, 4, 5, or 6 months.

28 . The method of claim 16 , wherein the cryogenic therapy causes regeneration of the treated nerves of stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion.

29 . The method of claim 16 , wherein the cryogenic therapy causes regeneration of one or more sodium channels of the treated nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion.

30 . The method of claim 16 , wherein the one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion comprise one or more desired nerves of a paravertebral chain.

31 . The method of claim 30 , wherein the one or more desired nerves of the paravertebral chain comprises one or more desired nerves of one or more of a C7 region of the paravertebral chain, a C8 region of the paravertebral chain, a T1 region of the paravertebral chain, and a T2 region of the paravertebral chain.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Aug 3, 2026
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: PACIRA CRYOTECH, INC.
Reel/Frame 075510/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2025
From: SPRANGER, JOHN; WINSTON, ROY; HAM, JARED; SLONIN, JONATHAN
To: PACIRA CRYOTECH, INC.
Reel/Frame 072719/0772 →
SECURITY INTEREST Recorded Jul 3, 2025
From: PACIRA CRYOTECH, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071609/0203 →
Continuity (3)
Provisional Application 63329286 · Apr 8, 2022
Provisional Application 63313698 · Feb 24, 2022
Related Publication 20230277233A1 · Sep 7, 2023
References Cited (32)
US 7713266B2 · Elkins et al. · 2010 [cited by applicant]
US 7850683B2 · Elkins et al. · 2010 [cited by applicant]
US 8298216B2 · Burger et al. · 2012 [cited by applicant]
US 8409185B2 · Burger et al. · 2013 [cited by applicant]
US 9039688B2 · Palmer et al. · 2015 [cited by applicant]
US 9254162B2 · Burger et al. · 2016 [cited by applicant]
US 10085881B2 · Karnik et al. · 2018 [cited by applicant]
US 11134998B2 · Cross et al. · 2021 [cited by applicant]
US 20120089211A1 · Curtis et al. · 2012 [cited by applicant]
US 20150065945A1 · Zarins · 2015 [cited by examiner]
US 20180116705A1 · Lee et al. · 2018 [cited by applicant]
US 20200100828A1 · Guzman · 2020 [cited by examiner]
US 20210330927A1 · Guzman · 2021 [cited by applicant]
US 20220133381A1 · Prologo · 2022 [cited by examiner]
US 20240382250A1 · Kamat · 2024 [cited by examiner]
WO WO2010075438 · 2010 [cited by applicant]
WO WO2010075448 · 2010 [cited by applicant]
WO WO2013134452 · 2013 [cited by applicant]
WO WO2020163854 · 2020 [cited by applicant]
WO WO2020163854A1 · 2020 [cited by examiner]
WO WO2022266327A1 · 2022 [cited by examiner]
Abrich et al., Jan. 10, 2017, Left stellate ganglion block: increasing clinical awareness in the eye of the electrical storm, American College of Cardiology, 7 pp. [cited by applicant]
Chatzidou et al., 2021, Cryoablation of stellate ganglion for the management of electrical storm: the first reported case, European Society of Cardiology, EP Case Report, 2 pp. [cited by applicant]
Chaudhry et al., Aug. 2018, Detection of the Stellate and Thoracic Sympathetic ChainGanglia with High-Resolution 3D-CISS MR Imaging, AJNR Am J Neuroradiol 39:1550-1554. [cited by applicant]
Garcia-Moran et al., 2016, Refractory electrical storm: a role for transient sympathetic blockade, Scientific Letters/Rev Esp Cardiol., 69:(1):75-85. [cited by applicant]
Hayase et al., Aug. 2013, Percutaneous Stellate Ganglion Block Suppressing VT and VF in a Patient Refractory to VT Ablation, Cardiovasc Electrophysiol. 24(8):1-6. [cited by applicant]
Leiria et al., 2011, Longterm effects of cardiac mediastinal nerve cryoablation on neural inducibility of atrial fibrillation in canines, Autonomic Neuroscience: Basic and Clinical, 161:68-74. [cited by applicant]
Meng et al., 2017, Efficacy of Stellate Ganglion Blockade in Managing Electrical Storm, JACC: Clinical Electrophysiology, 3(9):942-949. [cited by applicant]
Rebecchi et al., 2021, Atrial fibrillation and autonomic nervous system: A translational approach to guide therapeutic goals, Journal of Arrhythmia, 37:320-330. [cited by applicant]
Shelton et al., May 2018, Effects of Stellate Ganglion Cryoablation on Subcutaneous Nerve Activity and Atrial Tachyarrhythmias in a Canine Model of Pacing Induced Heart Failure, JACC Clin Electrophysiol. 4(5):686-695. [cited by applicant]
Tian et al., Sep. 2019, Effective Use of Percutaneous Stellate Ganglion Blockade in Patients With Electrical Storm, Circ Arrhythm Electrophysiol. 2019;12:e007118. [cited by applicant]
International Search Report and Written Opinion mailed Apr. 26, 2023 for PCT Application No. PCT/US2023/062945, filed Feb. 21, 2023 in 6 pages. [cited by applicant]